ACHILLION PHARMACEUTICALS INC

Delisted

CIK 0001070336AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2018

Revenue

—

Net Income

$-70.27M

Total Assets

$277.86M

Equity

$266.01M

Shares Out

140.05M

Op. Cash Flow

$-62.01M

Business

ACHILLION PHARMACEUTICALS INC is a former operating company in Pharmaceutical Preparations, incorporated in Delaware. Securities are no longer actively traded on a major U.S. exchange.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	—	—	15	66	—
Research and development	50	64	57	57	54
General and administrative	24	26	23	25	16
Restructuring charges (Note 3)	2	—	—	—	—
Total operating expenses	76	90	80	81	69
Loss from operations	−76	−90	−65	−15	−69
Interest income	6	4	3	1	455,000
Interest expense	−36,000	−50,000	−68,000	−55,000	−37,000
Net loss	−70	−85	−62	−5	−69
Unrealized income (loss) on marketable securities	190,000	−540,000	196,000	—	—
Total other comprehensive income (loss)	190,000	−540,000	196,000	−33,000	−18,000
Total comprehensive loss	−70	−86	−62	−5	−69
Basic and diluted net loss per share attributable to common stockholders (Note 4)	−0.51	−0.62	−0.45	−0.04	−0.7
Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders	138	137	137	126	98

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Cash and cash equivalents	50	43	77	82	74
Marketable securities	221	257	287	378	79
Accounts and other receivables	350,000	60,000	15	506,000	95,000
Prepaid expenses and other current assets	4	4	3	3	2
Total current assets	275	304	383	463	155
Marketable securities	0	31	28	—	—
Fixed assets, net	2	3	3	2	2
Other assets	189,000	196,000	52,000	50,000	54,000
Restricted cash	152,000	152,000	152,000	152,000	152,000
Total assets	278	338	414	465	157
Accounts payable	2	5	7	4	6
Accrued expenses	9	7	7	10	6
Current portion of long-term debt	131,000	170,000	351,000	223,000	195,000
Total current liabilities	12	13	14	15	13
Other long-term liabilities	17,000	83,000	149,000	—	—
Long-term debt	0	131,000	301,000	231,000	279,000
Total liabilities	12	13	14	15	13
Commitments and contingencies (Note 12)	—	—	—	—	—
Common Stock, $0.001 par value; 200,000 shares authorized at December 31, 2018 and 2017; 138,716 and 137,894 shares issued and outstanding at December 31, 2018 and 2017, respectively	139,000	138,000	137,000	137,000	104,000
Additional paid-in capital	939	927	917	905	600
Accumulated deficit	−673	−603	−517	−456	−451
Accumulated other comprehensive loss	−199,000	−389,000	151,000	−45,000	−12,000
Total stockholders' equity	266	325	399	450	143
Total liabilities and stockholders' equity	278	338	414	465	157

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Depreciation	1	1	955,000	694,000	489,000
Noncash stock-based compensation	9	11	11	10	7
Loss on disposal of equipment	49,000	—	8,000	2,000	−2,000
Premium on purchases of marketable securities	−59,000	−1	−565,000	−2	−947,000
Amortization of (discount) premium on marketable securities	−641,000	1	985,000	—	—
Accounts and other receivables	−290,000	15	−15	−411,000	385,000
Prepaid expenses and other current assets	−242,000	−313,000	−721,000	−837,000	575,000
Accounts payable	−3	−2	3	−2	2
Accrued expenses	2	834,000	−4	4	2
Other long-term liabilities	−66,000	−66,000	149,000	—	—
Net cash used in operating activities	−62	−59	−66	—	—
Purchase of fixed assets	−515,000	−626,000	−3	−704,000	−947,000
Purchase of marketable securities	−223	−345	−499	−693	−79
Maturities of marketable securities	290	372	562	395	124
Net cash provided by investing activities	66	26	61	—	—
Proceeds from exercise of stock options	2	39,000	108,000	4	4
Proceeds from sale of stock under the employee stock purchase plan	146,000	225,000	214,000	290,000	241,000
Payment of deferred financing costs	—	−175,000	—	—	—
Borrowings of debt	—	—	444,000	229,000	440,000
Repayments of debt	−170,000	−351,000	−246,000	−248,000	−313,000
Net cash provided by (used in) financing activities	2	−262,000	520,000	—	—
Net increase (decrease) in cash, cash equivalents and restricted cash	6	−34	−4	—	—
Cash paid for interest	37,000	52,000	46,000	—	—
Cashless exercise of warrants	—	9	—	53,000	3
Purchases of equipment in accounts payable or accrued expenses	49,000	36,000	199,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ACHILLION PHARMACEUTICALS INC's CIK number?

ACHILLION PHARMACEUTICALS INC's SEC CIK number is 0001070336 (1070336). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ACHILLION PHARMACEUTICALS INC's SEC filings?

All of ACHILLION PHARMACEUTICALS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →